U.S. Remote Patient Monitoring Market Size & Share 2026-2035

U.S. Remote Patient Monitoring Market Size

The U.S. remote patient monitoring market was valued at USD 13.32 billion in 2025, is expected to reach USD 15.03 billion in 2026, and is projected to expand at a compound annual growth rate of 8.5% from 2026 to 2035, reaching USD 31.32 billion by 2035.

The U.S. remote patient monitoring market is moving from point-solution adoption toward connected care architectures that combine prescription-grade devices, clinical software, and recurring monitoring services. Demand is increasingly shaped by the ability of providers and payers to operationalize continuous data collection within care-management workflows, particularly for chronic disease populations and post-acute home-based care.

U.S. Remote Patient Monitoring Market Trends, Growth Drivers & GMI Forecast Outlook

The market's next phase depends on whether reimbursement-supported monitoring programs can extend beyond established glucose and cardiac pathways without imposing unsustainable clinical, technical, or compliance burdens. Home-based care delivery, multisensor data integration, and payer willingness to fund longitudinal monitoring will determine the pace of expansion.

Key Drivers

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Diabetes creates a particularly durable enrollment base because its monitoring requirements extend across diagnosis, treatment adjustment, adherence management, and complication prevention. Prediabetes affects 115.2 million U.S. adults, widening the longer-term pool for metabolic-health programs, while the economic burden associated with diagnosed diabetes reinforces payer interest in earlier intervention and avoidable-utilization reduction ^{[1]Centers for Disease Control and Prevention. "Fast Facts: Health and Economic Costs of Chronic Conditions." cdc.gov}. The commercial opportunity is strongest where CGM data can be paired with established clinician workflows rather than offered as an isolated consumer-data stream.

Wearable convergence is broadening the strategic role of glucose data. Integration with sleep, activity, stress, and cardiovascular signals can make CGM platforms more relevant to metabolic-health programs, employer-sponsored benefits, and longitudinal care models. The FDA's clearance of Dexcom Stelo established an over-the-counter pathway for continuous glucose monitoring, creating a bridge between consumer adoption and clinically managed programs where evidence, reimbursement, and provider oversight align ^{[7]U.S. Food and Drug Administration. "FDA Clears First Over-the-Counter Continuous Glucose Monitor." fda.gov}.

CMS reimbursement infrastructure has altered the economics of remote monitoring by linking device setup, data transmission, and treatment management to recurring clinical workflows. That framework supports vendors that can reduce enrollment friction, document service delivery reliably, and integrate monitoring insights into care escalation. The Hospital at Home model further expands the role of RPM infrastructure where patients require observation beyond conventional inpatient settings.

Key Restraints

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Cybersecurity is a structural operating requirement rather than a discretionary technology expense for RPM suppliers. Continuous transmission from distributed devices, reliance on home connectivity, and third-party cloud and analytics partners widen the number of control points that must be secured. The pressure is especially acute for smaller providers and platform companies that must fund enterprise-grade safeguards while competing in device categories where hardware differentiation is narrowing.

Medicare billing scrutiny adds a second layer of execution risk. The Office of Inspector General's findings increase the importance of auditable ordering, enrollment, data-review, and treatment-management processes ^{[4]U.S. Department of Health and Human Services, Office of Inspector General. "Additional Oversight of Remote Patient Monitoring in Medicare Is Needed." oig.hhs.gov}. This favors established platforms with documentation discipline and embedded clinical operations, while smaller practices may defer launches when compliance administration exceeds the perceived near-term benefit.

Interoperability remains a practical bottleneck. Without consistent FHIR-based pathways into electronic health record environments, clinicians may need to review data through separate portals or manually reconcile alerts with existing records. The resulting workflow burden limits adoption in independent practices, rural providers, and safety-net settings that are often the least equipped to support customized integrations.

U.S. Remote Patient Monitoring Market Segment Analysis

By Product Type

Blood Glucose Monitoring (CGM)

Blood glucose monitoring is projected to hold a 32.0% share of the market by 2035, after generating USD 4.92 billion in 2025. CGM remains the central product category because glucose data supports recurring disease management, medication titration, and patient engagement. Its revenue mix is likely to become more diversified as prescription systems, over-the-counter products, and data-enabled metabolic-health programs address different patient and payer pathways.

Cardiac Monitoring

Cardiac monitoring accounted for 20.0% of the market in 2025 and is expected to generate USD 5.63 billion by 2035. The category benefits from entrenched clinical protocols for ambulatory ECG assessment and connected implantable-device follow-up. Demand is reinforced by the recurring nature of rhythm surveillance, which makes data interpretation, care-team responsiveness, and longitudinal device management as commercially important as the monitoring hardware itself.

Respiratory Monitoring

Respiratory monitoring generated USD 1.46 billion in 2025 and is projected to expand at a 10.3% CAGR from 2026 to 2035. Connected CPAP and BiPAP ecosystems anchor the segment through adherence-driven care models, while asthma and COPD monitoring broaden its clinical relevance. Growth depends on the ability to link home respiratory data with intervention pathways that improve adherence and reduce acute-care utilization.

Multiparameter Monitoring

Multiparameter monitoring is forecast to reach USD 3.44 billion by 2035 and expand at a 10.8% CAGR from 2026 to 2035. Hospital-at-home and post-discharge programs increasingly require a consolidated view of several physiological indicators rather than separate condition-specific devices. This favors wearable systems that reduce patient burden, enable clinically prioritized alerting, and support care teams managing higher-acuity populations outside conventional facilities.

Blood Pressure Monitoring

Blood pressure monitoring is expected to generate USD 2.50 billion by 2035, compared with an 8.0% market share in 2025. The category has a broad chronic-care foundation because hypertension management is compatible with physician-directed monitoring and routine treatment adjustment. Device commoditization may limit hardware pricing power, making software-supported adherence, clinician workflow integration, and recurring service delivery more important sources of differentiation.

Sleep Monitoring

Sleep monitoring generated USD 932 million in 2025 and is projected to account for 8.0% of the market by 2035. Its opportunity extends from diagnostic access to connected therapy management, particularly where home testing can lead directly into monitoring-supported sleep-apnea treatment. Vendors that connect diagnosis, adherence evidence, and respiratory-care management are better positioned than those offering stand-alone consumer sleep tracking.

Neurological Monitoring

Neurological monitoring held a 4.0% market share in 2025 and is projected to expand at a 13.0% CAGR from 2026 to 2035. The segment is gaining traction as wearables and digital biomarkers make symptom capture more feasible outside specialist visits. Parkinson's disease, epilepsy, rehabilitation, and movement-disorder applications require clinically credible interpretation, which creates room for differentiated platforms that can demonstrate decision support rather than simply collect signals.

Fetal & Neonatal Monitoring

Fetal and neonatal monitoring is expected to reach USD 940 million by 2035, from a 3.0% market share in 2025. Remote fetal surveillance can support high-risk pregnancy management when clinical protocols, care escalation, and reimbursement are clearly defined. Adoption remains sensitive to payer coverage and provider confidence in translating home-collected maternal and fetal data into safe obstetric decision-making.

Other Products

Other products represented approximately 1.0% of the market in 2025. This category includes specialized monitoring applications whose commercial expansion will depend on condition-specific evidence, regulatory authorization, and payer recognition rather than broad platform adoption alone.

By Application

Cardiovascular Diseases

Cardiovascular diseases generated USD 3.99 billion in 2025 and are projected to represent 26.0% of the market by 2035. The application is supported by established use cases in implantable-device follow-up, arrhythmia detection, heart-failure management, and hypertension monitoring. Its future growth is likely to depend on expanding monitoring beyond specialist cardiology settings while preserving the clinical responsiveness that makes cardiac alerts actionable.

Diabetes

Diabetes is projected to generate USD 10.02 billion by 2035, after accounting for 30.0% of the market in 2025. The application is positioned at the intersection of CGM adoption, medication management, and consumer interest in metabolic health. Expanded access through over-the-counter glucose monitoring can broaden awareness and trial, but sustained RPM revenue will rely on care models that connect data to clinician-guided intervention and reimbursement-supported management.

Respiratory Diseases

Respiratory diseases generated USD 1.73 billion in 2025 and are forecast to grow at a 9.2% CAGR from 2026 to 2035. Connected respiratory programs benefit from repeat engagement around sleep therapy adherence, chronic pulmonary disease management, and post-acute follow-up. Their value proposition is strongest when data collection supports timely therapy adjustment rather than retrospective reporting alone.

Neurological Disorders

Neurological disorders are projected to account for 8.0% of the market by 2035, following USD 1.06 billion in revenue in 2025. Home-based symptom monitoring can address a major limitation of episodic office assessments by capturing variation in tremor, dyskinesia, seizures, and functional recovery over time. Market development will depend on payer acceptance and clinical validation of monitoring endpoints across distinct neurological conditions.

Cancer

Cancer accounted for 7.0% of the market in 2025 and is projected to grow at a 10.1% CAGR from 2026 to 2035. Oncology monitoring carries substantial clinical value where remote vital signs and patient-reported signals can identify treatment toxicity or deterioration before an avoidable acute event. The segment requires tightly integrated escalation protocols, which can raise implementation complexity but also strengthen the case for premium clinical-service models.

Infectious Diseases

Infectious diseases are forecast to represent 3.0% of the market by 2035, after generating USD 532 million in 2025. The category is normalizing following pandemic-era demand, with the remaining opportunity concentrated in post-discharge surveillance and chronic infectious-disease care. Its episodic nature makes recurring revenue less durable than in chronic-condition applications, unless monitoring becomes embedded in broader comorbidity management programs.

Other Applications

Other applications are expected to reach USD 2.82 billion by 2035 and represented an 8.0% market share in 2025. Wound care, renal disease, rehabilitation, dermatology, and remote therapeutic monitoring offer a pipeline of targeted use cases. Commercial expansion will be determined by whether regulatory clearance, clinical evidence, and payer coverage mature in sufficient alignment to support scaled care delivery.

By End Use

Home-Care Settings

Home-care settings generated USD 8.25 billion in 2025 and are projected to account for 68.0% of the market by 2035. This setting is becoming the operational center of RPM because it allows monitoring to continue across chronic-care and post-discharge episodes without facility-based observation costs. The competitive advantage lies with suppliers that can make device deployment, patient onboarding, clinical review, and escalation reliable at population scale.

Long-Term Care

Long-term care is expected to generate USD 6.26 billion by 2035, after holding a 25.0% market share in 2025. Facilities retain a critical role for patients whose acuity, functional limitations, or care needs make home management unsuitable. However, the category faces relative pressure as clinically stable patients move into home-based pathways, requiring long-term care providers to concentrate monitoring resources on more complex populations.

Other End Use

Other end-use settings generated USD 1.73 billion in 2025 and are projected to grow at a 7.6% CAGR from 2026 to 2035. Hospital outpatient programs, specialty practices, employer health initiatives, and decentralized clinical trials provide diversification beyond conventional payer-funded home monitoring. Their scale will depend on the extent to which monitoring solutions can demonstrate operational value without relying on the same reimbursement mechanics as chronic disease RPM.

U.S. Remote Patient Monitoring Market Regional Analysis

United States Remote Patient Monitoring Market Analysis

The remote patient monitoring market in the United States represented 90.0% of the North American RPM market in 2025 and is projected to represent 89.0% by 2035. Its scale reflects a distinctive combination of reimbursement infrastructure, device availability, clinical digital-health investment, and large chronic-disease populations. The modest change in regional share does not alter the United States' position as the principal market for RPM commercialization in North America.

CMS billing pathways provide a level of revenue visibility that supports investment in connected devices, data platforms, and clinician-managed service models. The Hospital at Home program also strengthens demand for monitoring capabilities that can bridge inpatient, post-acute, and home-based care. Adoption remains uneven within the country: integrated delivery systems can deploy RPM across large populations, while rural providers and independent practices face more pronounced broadband, staffing, interoperability, and implementation constraints.

U.S. Remote Patient Monitoring Market Share & Competitive Landscape

The U.S. remote patient monitoring market share is moderately concentrated, with the five leading companies collectively accounting for approximately 47% of market revenue in 2025. Competition differs materially by product category: CGM, cardiac telemetry, respiratory therapy management, multiparameter monitoring, and clinical software each have distinct incumbent advantages. Scale, reimbursement expertise, installed device bases, data-platform capabilities, and clinical integration determine competitive positioning more than device hardware alone.

Abbott Laboratories

Abbott held a 13% market share in 2025. Its competitive position is anchored in the FreeStyle Libre ecosystem, which combines sensor deployment, patient-facing applications, and provider-accessible glucose data. Abbott's opportunity lies in extending the utility of its installed CGM base through analytics, connected care partnerships, and patient-management capabilities that reinforce retention in both prescription and consumer-adjacent channels.

Dexcom Inc.

Dexcom held a 13% market share in 2025. The company's CGM franchise is supported by its G-series systems, the Stelo over-the-counter offering, and provider-facing data-management tools. Its partnership with ŌURA illustrates a strategy focused on connecting glucose data with broader wearable biometrics, potentially extending Dexcom's relevance from diabetes management into wider metabolic-health and wellness-adjacent programs ^{[2]DexCom, Inc. "Dexcom and ŌURA Announce Strategic Partnership." investors.dexcom.com}.

Medtronic plc

Medtronic held an 11% market share in 2025. Its positioning spans glucose management, implantable cardiac-device telemetry, and acute-care monitoring, giving it exposure to both recurring chronic-care monitoring and higher-acuity clinical workflows. The company's installed base and integration across device categories support a differentiated ability to participate in care pathways where monitoring is linked to therapeutic intervention.

Boston Scientific

Boston Scientific competes primarily through cardiac diagnostic and remote follow-up platforms, including ambulatory ECG and implantable-monitoring ecosystems. Its positioning is strengthened by the growing need for efficient arrhythmia detection and longitudinal cardiac surveillance. As automated analysis becomes more embedded in cardiac workflows, platform usability, clinical confidence, and integration with diagnostic-service infrastructure will shape competitive gains.

GE Healthcare

GE Healthcare participates through maternal-fetal, neonatal, and connected patient-monitoring capabilities serving institutional care settings. Its established health-system relationships provide an advantage in high-risk obstetric and acute-care environments where RPM deployment requires clinical-grade hardware, workflow integration, and reliable escalation pathways.

Koninklijke Philips N.V.

Philips participates through connected respiratory therapy management, cardiac monitoring, and patient-monitoring platforms. Its position in home respiratory care is supported by the need for adherence visibility and clinician review in sleep-disordered breathing management. The company's strategic direction in patient care informatics will influence its ability to convert hardware relationships into broader RPM service opportunities.

Johnson & Johnson

Johnson & Johnson participates in cardiac and post-procedure monitoring through its MedTech portfolio, particularly where rhythm assessment and remote follow-up complement procedural care. Its RPM presence is more focused than that of specialized chronic-care monitoring companies, but its established clinical relationships support targeted participation in procedural and cardiovascular pathways.

F. Hoffmann-La Roche Ltd

Roche contributes to connected diabetes care through its blood glucose monitoring portfolio and data-integration capabilities. The company's relevance is increasingly linked to how traditional glucose-management tools can support interoperable, clinician-managed care models as continuous sensing becomes more prominent in diabetes monitoring.

Baxter International

Baxter's connected-care capabilities support institutional and transition-of-care monitoring, particularly for higher-acuity patients moving between hospital, post-acute, and home settings. Its competitive role is tied to workflow integration and vital-sign management rather than consumer-oriented RPM channels.

BIOTRONIK SE & Co. KG

BIOTRONIK competes in implantable cardiac device remote monitoring through its Home Monitoring platform. Automatic data transmission and remote follow-up workflows allow cardiology teams to manage clinically stable device patients while reducing routine in-person visit demands. The company's position depends on its cardiac implant base and the efficiency of its clinical monitoring ecosystem.

OMRON

OMRON participates through connected blood pressure monitoring and digital health capabilities supporting physician-directed hypertension management. Its opportunity is linked to the conversion of consumer-familiar devices into clinically integrated monitoring programs that can demonstrate adherence, improve treatment adjustment, and operate within reimbursable care pathways.

Sotera Wireless

Sotera Wireless addresses higher-acuity monitoring through wearable multiparameter platforms designed for hospital-at-home and sub-acute settings. Its value proposition rests on replacing fragmented monitoring configurations with continuous, clinically actionable surveillance suited to patients who need more oversight than conventional home health models provide.

VitalConnect

VitalConnect serves hospital-at-home, skilled nursing, and post-discharge programs through wearable biosensor technology and associated monitoring infrastructure. Its positioning benefits from demand for lower-burden, multi-vital-sign monitoring that can support early detection of deterioration while reducing the operational complexity of managing multiple devices.

Recent Industry Developments

The FDA granted 510(k) clearance to Nordic Kinetics AB for the Sine Monitoring Parkinson's Disease Tremor Dyskinesia Apple Watch System in June 2026. The authorization supports passive monitoring of Parkinson's disease symptoms using commercially available smartwatch hardware and illustrates growing regulatory acceptance of consumer-device substrates in clinically oriented neurological monitoring ^{[5]U.S. Food and Drug Administration. "Medical Devices that Incorporate Sensor-Based Digital Health Technology." fda.gov}.

The FDA cleared Boston Scientific's BodyGuardian Remote Monitoring System version 3.0 in January 2026. The development advances the company's ambulatory cardiac monitoring capabilities and reflects the continued progression of remote ECG platforms toward more integrated arrhythmia-analysis workflows ^{[5]U.S. Food and Drug Administration. "Medical Devices that Incorporate Sensor-Based Digital Health Technology." fda.gov}.